Literature DB >> 23356194

Cross-protection among unrelated leptospira pathogens serovars: an unfinished story.

Luis A Rosario1, Daniel F Arencibia, Yolanda E Suarez, Juan F Infante, Bárbara Y Valdés, Niurka Batista.   

Abstract

BACKGROUND: The World Health Organization considers leptospirosis the most neglected zoonotic disease in the last decades. One of the major obstacles in the developing of vaccines for the prevention of leptospirosis is the absence of cross-protection among unrelated serovars. It is accepted that cross-protection among related serovars is due to antibodies generated against lipopolysaccharides (LPs), whereas a cross-protection among unrelated serovars is rarely observed.
OBJECTIVES: The objective of the study was to ascertain the existence of cross-protection among vaccine strains of different serovars.
RESULTS: The results of this research demonstrated that a cross-protection among unrelated Leptospira serovars strain is possible. The Canicola strain is able to induce protection against homologous, Ballum and Copenhageni strains. The Mozdok strain induced protection only against a homologous challenge. Other strains showed a moderate cross-protection against a heterologous challenge.
CONCLUSIONS: These findings suggest that the Canicola and Mozdok strains are ideal candidates for developing a new vaccine formulation for use in Cuba.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23356194

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  6 in total

1.  Homologous microscopic agglutinating antibodies after natural infection with leptospires - results from a long term follow up of a cohort living in an endemic area.

Authors:  R Vimal Raj; K Vinod Kumar; A P Sugunan; K Natarajaseenivasan; P Vijayachari
Journal:  Pathog Glob Health       Date:  2017-06-23       Impact factor: 2.894

2.  Human leptospirosis: seroreactivity and genetic susceptibility in the population of São Miguel Island (Azores, Portugal).

Authors:  Lisa M Esteves; Sara M Bulhões; Claudia C Branco; Francisco M Mota; Clara Paiva; Rita Cabral; Maria Luisa Vieira; Luisa Mota-Vieira
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

3.  A Universal Vaccine against Leptospirosis: Are We Going in the Right Direction?

Authors:  André Alex Grassmann; Jéssica Dias Souza; Alan John Alexander McBride
Journal:  Front Immunol       Date:  2017-03-09       Impact factor: 7.561

4.  MAT cross-reactions or vaccine cross-protection: retrospective study of 863 leptospirosis canine cases.

Authors:  Geneviève André-Fontaine; Laetitia Triger
Journal:  Heliyon       Date:  2018-11-02

Review 5.  Leptospiral Immunoglobulin-Like Domain Proteins: Roles in Virulence and Immunity.

Authors:  David A Haake; James Matsunaga
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

6.  New strategies for Leptospira vaccine development based on LPS removal.

Authors:  Fabiana Lauretti-Ferreira; Paloma L D Silva; Naiara M Alcântara; Bruna F Silva; Isabele Grabher; Gisele O Souza; Erika Nakajima; Milena A Akamatsu; Silvio A Vasconcellos; Patricia A E Abreu; Eneas Carvalho; Elizabeth A L Martins; Paulo L Ho; Josefa B da Silva
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.